Top 100 Contractors in NAICS 325412: Pharmaceutical Preparation Manufacturing, FY2023

Parent companies by net contract obligations Oct 1, 2022 – Sep 30, 2023 Code page on GovTribe

The top 10 won 96% of FY2023 NAICS 325412 contract dollars

Ranking facts

Contract obligations
$12,774,835,827 Net of deobligations, by contracts coded NAICS 325412
Contractors
307 Parent companies with an obligation
Largest contractor
Mckesson Corporation $9.62 billion, 74.7% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV · Free to reuse with credit to GovTribe (CC BY 4.0)

Full ranking

Rank Contractor Net obligations Share Trend
1 $9,624,599,012
Rank history: #1 in FY2021, #2 in FY2022, #1 in FY2024 and #1 in FY2025; up 1 since FY2022.
2 $1,981,066,148
Rank history: #44 in FY2021, #1 in FY2022, not on the FY2024 list and #48 in FY2025; down 1 since FY2022.
3 $237,000,000
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
4 $133,482,973
Rank history: #10 in FY2021, #15 in FY2022 and not on the FY2024–FY2025 lists; up 11 since FY2022.
5 $125,526,228
Rank history: #8 in FY2021, #11 in FY2022, #3 in FY2024 and #3 in FY2025; up 6 since FY2022.
6 $94,754,251
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #68 in FY2025; up 120 since FY2022.
7 $80,550,000
Rank history: #16 in FY2021, #14 in FY2022, #7 in FY2024 and #6 in FY2025; up 7 since FY2022.
8 $50,649,404
Rank history: not on the FY2021 list, #13 in FY2022, #6 in FY2024 and #26 in FY2025; up 5 since FY2022.
9
Teva Pharmaceutical Industries Ltd. Through Teva Pharmaceuticals Usa, Inc.
$36,142,176
Rank history: #18 in FY2021, #20 in FY2022, #28 in FY2024 and not on the FY2025 list; up 11 since FY2022.
10 $35,084,665
Rank history: #95 in FY2021, #25 in FY2022, #40 in FY2024 and not on the FY2025 list; up 15 since FY2022.
11 $32,687,109
Rank history: #23 in FY2021, #24 in FY2022, #16 in FY2024 and #15 in FY2025; up 13 since FY2022.
12 $32,379,816
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
13 $26,753,869
Rank history: not on the FY2021 list, #27 in FY2022, #14 in FY2024 and #14 in FY2025; up 14 since FY2022.
14 $22,199,262
Rank history: not on the FY2021 list, #16 in FY2022, #18 in FY2024 and #13 in FY2025; up 2 since FY2022.
15 $21,875,231
Rank history: #33 in FY2021, #36 in FY2022, #17 in FY2024 and not on the FY2025 list; up 21 since FY2022.
16 $20,066,727
Rank history: #26 in FY2021, #31 in FY2022 and not on the FY2024–FY2025 lists; up 15 since FY2022.
17 $15,636,270
Rank history: #20 in FY2021, #23 in FY2022, #19 in FY2024 and not on the FY2025 list; up 6 since FY2022.
18 $10,556,689
Rank history: #31 in FY2021, #38 in FY2022, #30 in FY2024 and #37 in FY2025; up 20 since FY2022.
19 $10,497,710
Rank history: #75 in FY2021, #33 in FY2022, #27 in FY2024 and not on the FY2025 list; up 14 since FY2022.
20 $10,496,000
Rank history: #13 in FY2021, #9 in FY2022 and not on the FY2024–FY2025 lists; down 11 since FY2022.
21 $10,261,049
Rank history: #36 in FY2021, not on the FY2022 list, #29 in FY2024 and not on the FY2025 list; up 132 since FY2022.
22 $8,600,677
Rank history: not on the FY2021 list, #12 in FY2022, not on the FY2024 list and #4 in FY2025; down 10 since FY2022.
23 $8,522,400
Rank history: #39 in FY2021, #41 in FY2022, #35 in FY2024 and #30 in FY2025; up 18 since FY2022.
24 $7,290,924
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
25 $7,271,583
Rank history: #41 in FY2021, #61 in FY2022, #36 in FY2024 and not on the FY2025 list; up 36 since FY2022.
26 $6,565,458
Rank history: #24 in FY2021, #35 in FY2022, #26 in FY2024 and not on the FY2025 list; up 9 since FY2022.
27 $6,303,126
Rank history: #50 in FY2021, #55 in FY2022, #32 in FY2024 and #32 in FY2025; up 28 since FY2022.
28 $6,189,329
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #19 in FY2025; new.
29 $5,510,426
Rank history: not on the FY2021 list, #28 in FY2022, #24 in FY2024 and not on the FY2025 list; down 1 since FY2022.
30 $4,445,582
Rank history: #37 in FY2021, #49 in FY2022, #55 in FY2024 and #83 in FY2025; up 19 since FY2022.
31
Heyltex Corporation
$4,142,331
Rank history: not on the FY2021–FY2022 lists, #71 in FY2024 and not on the FY2025 list; new.
32 $3,966,776
Rank history: #65 in FY2021, #48 in FY2022, #33 in FY2024 and #33 in FY2025; up 16 since FY2022.
33 $3,372,401
Rank history: not on the FY2021–FY2022 lists, #65 in FY2024 and #51 in FY2025; new.
34 $3,110,024
Rank history: #58 in FY2021, #42 in FY2022, #67 in FY2024 and not on the FY2025 list; up 8 since FY2022.
35 $2,910,508
Rank history: #49 in FY2021, #63 in FY2022, #46 in FY2024 and not on the FY2025 list; up 28 since FY2022.
36 $2,432,346
Rank history: #62 in FY2021, #53 in FY2022, #42 in FY2024 and not on the FY2025 list; up 17 since FY2022.
37 $2,265,276
Rank history: #56 in FY2021, #43 in FY2022, #53 in FY2024 and not on the FY2025 list; up 6 since FY2022.
38 $2,145,191
Rank history: #29 in FY2021, #40 in FY2022, #64 in FY2024 and #55 in FY2025; up 2 since FY2022.
39 $2,124,557
Rank history: #84 in FY2021, #56 in FY2022 and not on the FY2024–FY2025 lists; up 17 since FY2022.
40 $2,121,117
Rank history: #59 in FY2021, #52 in FY2022, #54 in FY2024 and #44 in FY2025; up 12 since FY2022.
41 $2,104,640
Rank history: not on the FY2021 list, #92 in FY2022, #45 in FY2024 and not on the FY2025 list; up 51 since FY2022.
42 $2,026,789
Rank history: #61 in FY2021, #64 in FY2022, #52 in FY2024 and #61 in FY2025; up 22 since FY2022.
43 $1,969,993
Rank history: #5 in FY2021, #5 in FY2022, #31 in FY2024 and #23 in FY2025; down 38 since FY2022.
44 $1,948,088
Rank history: #97 in FY2021, #60 in FY2022, #97 in FY2024 and not on the FY2025 list; up 16 since FY2022.
45 $1,947,803
Rank history: #35 in FY2021, #62 in FY2022, #83 in FY2024 and #52 in FY2025; up 17 since FY2022.
46 $1,824,103
Rank history: #51 in FY2021, #46 in FY2022, #79 in FY2024 and not on the FY2025 list; unchanged since FY2022.
47 $1,781,510
Rank history: #80 in FY2021, #69 in FY2022, #50 in FY2024 and #97 in FY2025; up 22 since FY2022.
48 $1,759,217
Rank history: #45 in FY2021, not on the FY2022 list and not on the FY2024–FY2025 lists; returned.
49 $1,706,483
Rank history: #70 in FY2021, #70 in FY2022, #43 in FY2024 and #75 in FY2025; up 21 since FY2022.
50 $1,684,170
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
51 $1,641,668
Rank history: #19 in FY2021, #19 in FY2022, #85 in FY2024 and not on the FY2025 list; down 32 since FY2022.
52 $1,629,953
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #10 in FY2025; new.
53 $1,500,000
Rank history: not on the FY2021 list, #87 in FY2022 and not on the FY2024–FY2025 lists; up 34 since FY2022.
54 $1,497,999
Rank history: #69 in FY2021, #75 in FY2022 and not on the FY2024–FY2025 lists; up 21 since FY2022.
55 $1,443,859
Rank history: #60 in FY2021, #66 in FY2022, #61 in FY2024 and #54 in FY2025; up 11 since FY2022.
56 $1,321,294
Rank history: not on the FY2021 list, #37 in FY2022 and not on the FY2024–FY2025 lists; down 19 since FY2022.
57 $1,315,621
Rank history: #52 in FY2021, #71 in FY2022, #70 in FY2024 and #35 in FY2025; up 14 since FY2022.
58 $1,195,100
Rank history: #71 in FY2021, #72 in FY2022, #93 in FY2024 and not on the FY2025 list; up 14 since FY2022.
59 $1,170,903
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #53 in FY2025; new.
60
Jazz Pharmaceuticals Inc.
$1,119,755
Rank history: not on the FY2021 list, #89 in FY2022, #48 in FY2024 and #49 in FY2025; up 29 since FY2022.
61 $1,060,237
Rank history: not on the FY2021 list, #67 in FY2022, #56 in FY2024 and #88 in FY2025; up 6 since FY2022.
62 $1,024,202
Rank history: not on the FY2021 list, #97 in FY2022, #57 in FY2024 and not on the FY2025 list; up 35 since FY2022.
63 $1,023,313
Rank history: #40 in FY2021, #47 in FY2022, #47 in FY2024 and not on the FY2025 list; down 16 since FY2022.
64 $994,264
Rank history: not on the FY2021–FY2022 lists, #80 in FY2024 and not on the FY2025 list; new.
65 $947,212
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 64 since FY2022.
66
AHS Hillcrest Medical Center LLC Through Topeka Hospital, LLC
$917,191
Rank history: not on the FY2021 list, #73 in FY2022 and not on the FY2024–FY2025 lists; up 7 since FY2022.
67
Cambridge Isotope Laboratories Inc. Through Otsuka America Pharmaceutical Inc.
$898,520
Rank history: #67 in FY2021, #58 in FY2022 and not on the FY2024–FY2025 lists; down 9 since FY2022.
68 $875,200
Rank history: not on the FY2021 list, #99 in FY2022, #39 in FY2024 and #45 in FY2025; up 31 since FY2022.
69 $845,416
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 48 since FY2022.
70 $811,631
Rank history: #48 in FY2021, #50 in FY2022, #37 in FY2024 and #38 in FY2025; down 20 since FY2022.
71
Grifols Diagnostic Solutions Inc. 2 awardees, including Grifols USA LLC
$785,573
Rank history: #90 in FY2021, not on the FY2022 list, #86 in FY2024 and not on the FY2025 list; up 33 since FY2022.
72 $753,934
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
73 $714,605
Rank history: not on the FY2021–FY2022 lists, #73 in FY2024 and #74 in FY2025; up 32 since FY2022.
74 $662,391
Rank history: #32 in FY2021, #26 in FY2022, not on the FY2024 list and #42 in FY2025; down 48 since FY2022.
75
Xellia Pharmaceuticals USA LLC
$661,450
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
76 $655,608
Rank history: #74 in FY2021, not on the FY2022 list and not on the FY2024–FY2025 lists; up 48 since FY2022.
77 $653,398
Rank history: not on the FY2021–FY2022 lists, #41 in FY2024 and not on the FY2025 list; up 58 since FY2022.
78
Alamo Nuclear Pharmacy Services Inc
$641,120
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
79 $640,399
Rank history: not on the FY2021 list, #88 in FY2022, #94 in FY2024 and not on the FY2025 list; up 9 since FY2022.
80
Otsuka Holdings Co. Ltd. Through Otsuka America Pharmaceutical Inc.
$634,774
Rank history: not on the FY2021–FY2022 lists, #60 in FY2024 and #73 in FY2025; new.
81 $626,988
Rank history: not on the FY2021–FY2022 lists, not on the FY2024 list and #71 in FY2025; up 38 since FY2022.
82 $619,377
Rank history: not on the FY2021–FY2022 lists, #90 in FY2024 and #70 in FY2025; up 45 since FY2022.
83 $612,037
Rank history: #14 in FY2021, not on the FY2022 list, #99 in FY2024 and not on the FY2025 list; up 172 since FY2022.
84 $600,000
Rank history: #93 in FY2021, #90 in FY2022 and not on the FY2024–FY2025 lists; up 6 since FY2022.
85
Austin Nuclear Pharmacy Services LLC
$594,302
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
86 $584,604
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 95 since FY2022.
87
Recordati Rare Diseases,
$567,160
Rank history: not on the FY2021 list, #81 in FY2022, #91 in FY2024 and not on the FY2025 list; down 6 since FY2022.
88 $561,131
Rank history: #87 in FY2021, #51 in FY2022 and not on the FY2024–FY2025 lists; down 37 since FY2022.
89
Roche Diabetes Care Inc Through Genentech Usa, Inc.
$552,642
Rank history: not on the FY2021–FY2022 lists, #2 in FY2024 and not on the FY2025 list; new.
90 $529,877
Rank history: not on the FY2021–FY2022 lists, #76 in FY2024 and not on the FY2025 list; up 19 since FY2022.
91 $504,812
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 53 since FY2022.
92 $495,665
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 38 since FY2022.
93
American Regent Inc
$486,679
Rank history: not on the FY2021–FY2022 lists, #87 in FY2024 and #50 in FY2025; new.
94 $466,364
Rank history: not on the FY2021–FY2022 lists, #89 in FY2024 and not on the FY2025 list; up 83 since FY2022.
95 $459,102
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; new.
96 $438,971
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 185 since FY2022.
97 $436,105
Rank history: not on the FY2021 list, #98 in FY2022, not on the FY2024 list and #78 in FY2025; up 1 since FY2022.
98 $433,014
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 8 since FY2022.
99 $416,020
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 91 since FY2022.
100 $402,256
Rank history: not on the FY2021–FY2022 lists and not on the FY2024–FY2025 lists; up 25 since FY2022.
Show 75 more

100 of 307 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $12.9 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2023 ran Oct 1, 2022 – Sep 30, 2023. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2022. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2022 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 NAICS 325412 contractors in FY2023?

1. Mckesson Corporation ($9.62B), 2. Pfizer Inc. ($1.98B), 3. Osang LLC ($237M), 4. Emergent Biosolutions Inc. ($133M), 5. Bavarian Nordic A / S ($126M), 6. Danaher Corporation ($94.8M), 7. Government of the United States ($80.6M), 8. Phlow Corp. ($50.6M), 9. Teva Pharmaceutical Industries Ltd. ($36.1M), 10. SANOFI ($35.1M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work